Sabari Joshua K, Paik Paul K
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Medical College, New York, NY, USA.
Ann Transl Med. 2017 Sep;5(18):373. doi: 10.21037/atm.2017.06.72.
The precision medicine revolution has led to the development and US FDA approval of multiple targeted therapies in non-squamous non-small cell lung cancers, including tyrosine kinase inhibitors targeting , , and . However, the development of targeted therapies for squamous cell lung cancers (SQCLCs) and small cell lung cancers (SCLCs) has lagged behind and the mainstay of systemic therapy for most patients with metastatic disease remains chemotherapy; which has seen little meaningful progress over the past three decades. The ideal of precision medicine in these diseases may appear elusive; however, recent comprehensive genomic analysis of SQCLC and SCLC has led to multiple breakthroughs in our understanding of the biology of these diseases and has led to new therapeutic approaches currently under active clinical investigation. This review will focus on the therapeutic relevance of these alterations in their respective diseases and new insights into promising therapeutics currently under investigation.
精准医学革命推动了多种针对非鳞状非小细胞肺癌的靶向疗法的研发并获得了美国食品药品监督管理局（FDA）的批准，这些疗法包括针对 、 和 的酪氨酸激酶抑制剂。然而，鳞状细胞肺癌（SQCLCs）和小细胞肺癌（SCLCs）靶向疗法的研发滞后，对于大多数转移性疾病患者而言，全身治疗的主要手段仍然是化疗；在过去三十年里，化疗几乎没有取得有意义的进展。在这些疾病中实现精准医学的理想似乎遥不可及；然而，最近对SQCLC和SCLC进行的全面基因组分析在我们对这些疾病生物学的理解上取得了多项突破，并催生了目前正在积极进行临床研究的新治疗方法。本综述将聚焦于这些改变在各自疾病中的治疗相关性以及对目前正在研究的有前景疗法的新见解。
